<DOC>
	<DOCNO>NCT00967902</DOCNO>
	<brief_summary>To demonstrate safety effectiveness Combo Bio-engineered Sirolimus Eluting Stent ( Combo Stent ) compare Taxus® Liberté® Stent treatment coronary artery lesion .</brief_summary>
	<brief_title>Safety Effectiveness Study Combo Bio-engineered Sirolimus Eluting Stent</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>General Inclusion Criteria The patient must ≥18 ≤ 80 year age ; Symptomatic ischemic heart disease ( CCS class 14 , Braunwald Class IB , IC , IIB , IIC , IIIB , IIIC , and/or objective evidence myocardial ischemia ) ; Acceptable candidate CABG ; The Patient willing comply specify followup evaluation ; The Patient legally authorize representative inform nature study , agree provision provide write informed consent , approve appropriate Medical Ethics Committee ( MEC ) , Institutional Review Board ( IRB ) , Human Research Ethics Committee ( HREC ) . Angiographic Single de novo nonstented restenotic lesion target vessel ; Patients twovessel coronary disease , may undergo successful treatment ( &lt; 20 % diameter stenosis visual estimate ) nontarget vessel approve device include index procedure must prior index target vessel treatment . Any nontarget vessel lesion intend treated index procedure , unprotected leave main , ostial lesion , chronic total occlusion ( CTO ) , heavily calcify , bifurcation , vein graft , angiographic evidence thrombus , anything require atherectomy , thrombectomy , pretreatment anything balloon angioplasty ; Target lesion locate native coronary artery ; Target lesion ( maximum length 20 mm visual estimate ) cover single stent maximum 23 mm length Combo Stent , 24 mm length TAXUS® Liberté® ( stent coverage include least 3 mm healthy vessel recommend ) . The lesion length measure predilation procedure ; Reference vessel diameter must ≥2.5 ≤ 3.5 mm visual estimate . The vessel diameter measure predilation procedure intracoronary nitroglycerin spasm suspect ; Target lesion ≥50 % &lt; 100 % stenosed visual estimate . General Pregnant nursing patient plan pregnancy period 1 year follow index procedure . Female patient childbearing potential must negative pregnancy test do within 7 day prior index procedure per site standard test ; Patient know diagnosis acute myocardial infarction ( AMI ) within 72 hour precede index procedure ( elevate troponin CKMB ≥2 time upper limit normal ) &gt; 72 hour precede index procedure CK CKMB return within normal limit time procedure ; The patient currently experience clinical symptom consistent new onset AMI , nitrate unresponsive prolong chest pain ; Impaired renal function ( serum creatinine &gt; 2.0 mg/dL 177 μmol/l ) dialysis ; Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 WBC &lt; 3,000 cells/mm3 ; Patient history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulant therapy contraindicate ; Patient require low molecular weight heparin ( LMWH ) treatment postprocedure receive dose LMWH ≤8 hour prior index procedure ; Patient receive organ transplant wait list organ transplant ; Patient medical illness ( e.g. , cancer , know malignancy , congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol , confound data interpretation associate limited life expectancy ( i.e. , less 1 year ) ; Patient know hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/ticlopidine , prasugrel , stainless steel alloy , sirolimus , paclitaxel and/or contrast sensitivity adequately premedicated ; Patient previously receive murine therapeutic antibody exhibit sensitization production Human AntiMurine Antibodies ( HAMA ) ; Patient present cardiogenic shock ; Patient current unstable cardiac arrhythmia create hemodynamic instability ; Patient extensive peripheral vascular disease precludes safe 6 French sheath insertion ; Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study ; Currently participate another investigational drug device study patient inclusion another investigational drug device study followup ; Angiographic Unprotected leave main coronary artery disease ≥50 % stenosis ; Ostial target lesion ( ) ; Totally occlude target vessel ( TIMI flow 0 ) ; Calcified target lesion ( ) successfully predilated ; Target lesion excessive tortuosity unsuitable stent delivery deployment ; Angiographic evidence thrombus target lesion ( ) ; Target lesion involve bifurcation side branch ≥2.0 mm diameter ( either stenosis main vessel major side branch stenosis major side branch ) would require intervention diseased side branch ; A significant ( &gt; 50 % ) stenosis proximal distal target lesion cover single stent ; Diffuse distal disease target lesion impair runoff ; Left ventricular ejection fraction ( LVEF ) ≤30 % ( LVEF must obtain within 6 month prior index procedure ) ; Pretreatment device balloon angioplasty ; Prior stent within 10 mm target lesion ; Intervention ( PCI bypass ) another lesion perform within 6 month plan within 30 day follow index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>intracoronary stent</keyword>
	<keyword>drug elute stent</keyword>
	<keyword>sirolimus</keyword>
	<keyword>endothelial progenitor cell</keyword>
</DOC>